Stifel initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00

Piper Sandler initiated coverage of Definium Therapeutics with a rating of Overweight and set a new price target of $49.00

Wolfe Research initiated coverage of Definium Therapeutics with a rating of Outperform and set a new price target of $25.00

Jefferies initiated coverage of Definium Therapeutics with a rating of Buy and set a new price target of $30.00

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to thirteen newly hired non-executive employees consisting of options to purchase an aggregate of 462,190 common shares of the Company (the "Options") with effective grant dates of May 18, 2026 and June 1, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversar

Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference in New York on Wednesday, June 3, 2026 at 3:10 p.m. EDT. Audio webcasts and replays of available presentations will be accessible on Definium's Investor Relations website for up to 90 days following each event. About Definium Therapeutics The mission of Definium Therapeutics is to forge a new era of psychiatry by applying scie

The primary endpoint will measure the change from baseline in the Montgomery-Åsberg Depression Rating Scale (MADRS) score at Week 6 between DT120 Orally Disintegrating Tablet (ODT) 100 µg and placebo Ascend builds on positive Phase 2b study results in generalized anxiety disorder, which showed the potential antidepressant effects of DT120 Topline data from the 12-week double-blind period is anticipated in 2027 Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of psychiatric and neurological disorders, today announced that the firs

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 255,340 common shares of the Company (the "Options") with effective grant dates of April 27, 2026, May 4, 2026 and May 11, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first

Three Phase 3 topline data readouts for DT120 ODT expected in the coming months DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027 $373.4 million in cash, cash equivalents, and investments as of March 31, 2026, expected to fund operations into 2028 Conference call scheduled today at 4:30 p.m. EDT Definium Therapeutics, Inc. ("Definium" or the "Company") (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today reported financial results for the quarter ended March 31, 2026, and recent highlights. "After an

Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that it will host a live webcast at 4:30 p.m. EDT on Thursday, May 7, 2026 to report financial results for the first quarter ended March 31, 2026, and discuss recent business highlights. Listeners can register for the webcast via this link. Analysts wishing to participate in the question and answer session should use this link. A replay of the webcast will be available via the Investor Relations section of the Definium Therapeutics website, ir.definiumtx.com, a

MDD: Emerge topline data readout on track for late 2Q 2026; Ascend sites activated with first patient dosing anticipated in 2Q 2026 GAD: Voyage enrollment complete with 214 patients with topline data readout on track for early 3Q 2026; Panorama sample size re-estimation complete and target sample size updated to 200; screening closed with topline readout now expected in late 3Q 2026 PTSD: DT120 ODT program expanded into PTSD with Phase 3 Haven study expected to initiate in 2027 Definium Therapeutics, Inc. (NASDAQ:DFTX) ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address the underlying causes of

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced the issuance of inducement grants to five newly hired non-executive employees consisting of options to purchase an aggregate of 70,860 common shares of the Company (the "Options") with effective grant dates of April 6, 2026 and April 20, 2026. The Options have an exercise price equal to the closing price of Definium's common shares on the date of the respective grant, and will vest over a four-year period with 25% vesting on the first anniversary

Definium Therapeutics, Inc. ("Definium" or the "Company"), a late-stage clinical biopharmaceutical company developing a new generation of therapies targeting the underlying causes of psychiatric and neurological disorders, today issued the following statement supporting the newly signed White House Executive Order aimed at accelerating research, development, and responsible access to innovative treatments for serious mental illness, including emerging psychedelic medical treatments: "Accelerating scientific progress depends on both rigor and urgency, and we thank the Administration and welcome this Executive Order as an important recognition of the persistent unmet treatment needs in seri

Definium Therapeutics, Inc. (NASDAQ:DFTX), a late-stage clinical biopharmaceutical company developing a new generation of therapeutics intended to address underlying causes of psychiatric and neurological disorders, today announced that members of the Company's management team will participate in the following investor conferences and events: 25th Annual Needham Virtual Healthcare Conference Fireside Chat Date and Time: Thursday, April 16, 2026 at 3:00 PM EDT Webcast Link: 25th Annual Needham Virtual Healthcare Conference Definium Therapeutics Investor & Analyst Day Date and Time: Wednesday, April 22, 2026 from 10:00 AM – 12:00 PM EDT (followed by lunch) Location: Well& b